Moody's Corporation (MCOR34)
B3 Stock Exchange · Brazil · prices in BRL · close of 26 Oct 2026
Key indicators
| Last close | BRL 82.09 |
|---|---|
| 52-week range | 66.45 – 90.59 |
| Return, 1 month / 3 months | +7.9% / +6.2% |
| Return, 1 year / 3 years | +3.1% / +88.5% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 30.9% |
| Worst drawdown (1 year) | -26.6% |
| Average daily value traded | 0.02M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Moody's Corporation is a financial information and analytics company based in New York. Through its ratings business it assigns credit ratings to debt issued by companies, governments and other borrowers, helping investors judge the risk of those obligations. Its analytics arm supplies research, data, software and risk-management tools to banks, asset managers, insurers and other institutions. Customers around the world use these services to assess credit risk and make informed decisions about lending and investment.
Moody's Corporation is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code MCOR34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Moody's Corporation (MCOR34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 82.09 on 26 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 470 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.1% and over the last three months it rose 6.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 10.3% | ||
| From 52-week high | -9.4% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.2% | ||
| 6-month return | 16.4% | ||
| 12-month return, skipping the last month | -4.5% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.6% | ||
| Liquidity | 45 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M BRL | ||
| Zero-volume days | 30.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +8.1% |
|---|---|
| 1 month | +7.9% |
| 3 months | +6.2% |
| 6 months | +16.4% |
| 1 year | +3.1% |
| 3 years | +88.5% |
| 5 years | +63.2% |
Signals
| 50-day / 200-day average | 76.71 / 74.41 |
|---|---|
| Golden / death cross (60 days) | Golden, 50 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Aug 2026 | USD 0.1103 |
| 13 May 2026 | USD 7.2025 |
| 26 Feb 2026 | USD 7.3351 |
| 18 Nov 2025 | USD 6.8572 |
| 13 Aug 2025 | USD 6.9016 |
| 14 May 2025 | USD 7.0901 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.